Oral Supplementation of Lutein/Zeaxanthin and Omega-3 Long Chain Polyunsaturated Fatty Acids in Persons Aged 60 Years or Older, with or without AMD
| Autor: | Wai T. Wong, Francisco M. de Monasterio, Rosemary L. Schleicher, Jonghyeon Kim, Emily Y. Chew, Hanna R. Coleman, Frederick L. Ferris, Lynn L. Huang |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Lutein medicine.medical_specialty Time Factors Visual Acuity Xanthophylls Placebos Macular Degeneration chemistry.chemical_compound Reference Values Zeaxanthins Internal medicine Fatty Acids Omega-3 medicine Humans Carotenoid Aged chemistry.chemical_classification business.industry food and beverages Middle Aged Macular degeneration medicine.disease Eicosapentaenoic acid eye diseases Zeaxanthin Endocrinology chemistry Biochemistry Docosahexaenoic acid Xanthophyll Dietary Supplements Female sense organs business Polyunsaturated fatty acid |
| Zdroj: | Investigative Opthalmology & Visual Science. 49:3864 |
| ISSN: | 1552-5783 |
| Popis: | PURPOSE Increased dietary intake of lutein/zeaxanthin and omega-long-chain polyunsaturated fatty acids (omega-3 LCPUFA) was found to be associated with reduced risk of advanced age-related macular degeneration (AMD). The purpose of the study was to examine the effect of oral supplementation of omega-3 LCPUFA on changes in serum levels of lutein/zeaxanthin during supplementation in persons 60 years of age and older, with or without AMD. METHODS Forty participants with AMD of various degrees of severity received lutein (10 mg) and zeaxanthin (2 mg) daily and were equally randomized to receive omega-3 LCPUFA (350 mg docosahexaenoic acid [DHA] and 650 mg eicosapentaenoic acid [EPA]) or placebo for 6 months. Serum levels of lutein, zeaxanthin, and omega-3 LCPUFAs and macular pigment optical densities were measured at baseline, 1 week, and 1, 3, 6, and 9 months. RESULTS By month 6, the median serum levels of lutein/zeaxanthin increased by two- to threefold compared with baseline. Increases in serum levels of lutein/zeaxanthin did not differ by omega-3 LCPUFA treatment (P > 0.5). After 1 month, in the omega-3 LCPUFA-treated group, the median levels of DHA and EPA increased and the placebo group had no changes. At month 6, participants with AMD had a lower increase in serum lutein concentration than did those without AMD (P < 0.05). CONCLUSIONS The addition of omega-3 LCPUFA to oral supplementation of lutein/zeaxanthin did not change the serum levels of lutein and zeaxanthin. A long-term large clinical trial is necessary to investigate the benefits and adverse effects of these factors for the treatment of AMD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|